Ipamorelin
Growth hormone-releasing peptide (GHRP)
The gentlest GHRP.
Half-life
~ 2 hours
Mol. weight
711.9 g/mol
Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2
Discussions
0 threads
Overview
A synthetic pentapeptide and selective ghrelin-receptor (GHS-R1a) agonist that stimulates growth hormone release from the pituitary with notably minimal effects on cortisol, prolactin, and appetite. Its selectivity is the reason it is the most-favored GHRP for research protocols aimed at body composition rather than hunger stimulation.
Mechanism of action
Ipamorelin agonizes the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus, triggering growth hormone release. Unlike GHRP-6 and GHRP-2, it was engineered for greater receptor selectivity, producing robust GH pulses with far less appetite stimulation and minimal cortisol/prolactin elevation. That clean profile — strong GH signal, few off-target hormonal effects — is why it pairs so well with GHRH analogs like CJC-1295 in synergistic stacks.
Researched benefits
- Stimulates GH release with minimal cortisol impact
- Far less appetite stimulation than other GHRPs
- Minimal prolactin elevation
- Pairs well with GHRH analogs for synergy
Considerations
- Effects are gradual, not acute
- Quality sourcing critical
- Professional guidance advised
Key Academic Literature & Studies
Search more in PubMedPeer-reviewed citations and clinical trials evaluating Ipamorelin in scientific literature.
Query PubMed for recent peer-reviewed preclinical and clinical publications on Ipamorelin:
View Ipamorelin index on PubMed (NCBI)